In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

Filed: September 5, 2019

* * * * * * * * * * * * *

G.C. by her parent BRYNN CONTINO, * PUBLISHED

*

Petitioner, * No. 15-773V

*

v. * Special Master Gowen

*

SECRETARY OF HEALTH * Entitlement; Influenza (“flu”); 

AND HUMAN SERVICES, * Urticarial Vasculitis; Bystander

* Activation. 

Respondent. *

* * * * * * * * * * * * *

Lawrence R. Cohan, Anapol Weiss, Philadelphia, PA, for petitioners.

Darryl R. Wishard, United States Department of Justice, Washington, DC, for respondent. 

RULING ON ENTITLEMENT1

On July 23, 2015, Brynn Contino (“petitioner”), on behalf of her minor child, G.C., filed 

a petition in the National Vaccine Injury Compensation Program.2 Petitioner alleges that G.C. 

developed urticarial/hypersensitivity vasculitis which was caused in fact by the influenza (“flu”) 

vaccination received on December 3, 2013. Petition at Preamble. Based upon a full review of 

all of the evidence and testimony presented, I find that petitioner is entitled to compensation.3

 

1

In accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012), because this opinion contains a 

reasoned explanation for the action in this case, this opinion will be posted on the website of the United States 

Court of Federal Claims. This means the opinion will be available to anyone with access to the internet. As 

provided by 42 U.S.C. § 300aa-12(d)(4)B), however, the parties may object to the published Decision’s inclusion of 

certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party has 14 days within 

which to request redaction “of any information furnished by that party: (1) that is a trade secret or commercial or 

financial in substance and is privileged or confidential; or (2) that includes medical files or similar files, the 

disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). If neither 

party files a motion for redaction within 14 days, the entire opinion will be posted on the website and available 

to the public in its current form. Id.

2 The National Vaccine Injury Compensation Program is set forth in Part 2 of the National Childhood Vaccine 

Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended, 42 U.S.C. §§ 300aa-10 to 34 (2012) 

(hereinafter “Vaccine Act” or “the Act”). Hereinafter, individual section references will be to 42 U.S.C. § 300aa of 

the Act.

3 Pursuant to Section 300aa-13(a)(1), in order to reach my conclusion, I have considered the entire record including 

all of the medical records, statements, expert reports, and medical literature submitted by the parties. This opinion

discusses the elements of the record I found most relevant to the outcome.

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 1 of 25
2

I. BACKGROUND

A. Procedural History

On July 23, 2015, petitioner filed her claim that G.C.’s December 13, 2013 flu 

vaccination was the cause-in-fact of her development of urticarial/hypersensitivity vasculitis. 

Petition (ECF No. 1). An initial status conference was held on September 1, 2015. Scheduling 

Order (ECF No. 7). Respondent indicated that he would like to review an expert report from 

petitioner prior to determining on how to proceed. Id. Petitioner was ordered to file all medical 

records and an expert report. Id. 

On October 28, 2015, petitioner filed medical records.4 Petitioner’s (“Pet.”) Exhibit 

(“Ex.”) 5 (ECF No. 9). Then on November 18 and 19, 2015, petitioner filed her first expert 

report from Dr. Vera Byers5and supporting medical literature. Pet. Exs. 6-8(1) (ECF Nos. 10-

12). On February 5, 2016, respondent filed his first expert report by Dr. Harry Schroeder, Jr.6

and supporting medical literature. Respondent’s (“Resp.”) Ex. A (ECF No. 16). 

 

4 With the petition, petitioner filed a Notice of Intent to File Medical Records via compact disc (“CD”). Exhibits 1-4 

were filed via CD. ECF No. 1. 

5 Dr. Vera Byers obtained a bachelor’s degree in microbiology in 1965, a M.A. in microbiology in 1967, and a Ph.D 

in immunology in 1969, all from the University of California-Los Angeles (UCLA) Pet. Ex. 7 at 1; Tr. 54. She 

completed a fellowship in protein chemistry at Abbott Laboratories from 1969-1971 and a fellowship in clinical 

immunology and allergy from 1971-1973. Pet. Ex. 7 at 1. She testified that during this fellowship, she saw and 

treated rheumatology patients as well as those with genetic immunodeficiencies. Tr. 55. She obtained an M.D. in 

1981, then completed a three-year residency in internal medicine from 1981-1984, all from the University of 

California-San Francisco (UCSF). From 1984-1987, Dr. Byers work at Immunology Incorporated Medical Group in 

California, which was a private medical practice where she saw patients with rheumatology and allergy/immunology 

issues. Tr. 55; Pet. Ex. 7 at 3. Dr. Byers testified that she has diagnosed and treated patients with chronic urticaria 

and vasculitis. Tr. 58. Dr. Byers is currently the medical director and a consulting medical toxicologist for 

pharmaceutical companies at Immunology Inc. Pet. Ex. 7 at 2. She has frequently served as an expert witness in 

civil litigation and in the Vaccine program, where she has previously been qualified as an expert in immunology. In 

this case, petitioner proffered and I accepted Dr. Byers as an expert in the area of clinical immunology, particularly 

as it relates to evaluating and determining whether particular vaccines can trigger autoimmune diseases, including 

urticarial vasculitis. 

6 Dr. Harry Schroeder obtained a bachelor’s degree in chemistry in 1974 from Texas A&M University, a M.D. from 

Baylor College of Medicine in 1981 and a Ph.D. in cell biology in 1979 from Baylor College of Medicine. Resp. 

Ex. B. He testified that he did his residency at the University of Kentucky in Lexington, Kentucky. Tr. 204. Dr. 

Schroeder then went to the University of Washington where he obtained training in medical genetics. Id. He is 

board certified in internal medical and clinical genetics. Id. From 1986-1988 he pursued training in immunology, 

molecular immunology at the Howard Hughes Institute in Seattle, Washington. Resp. Ex. B at 2; Tr. 204. Dr. 

Schroeder began a teaching career at the University of Alabama at Birmingham in 1988. Tr. 204. Dr. Schroeder 

spent a sabbatical year at the University of Cologne in Cologne Germany at the Institute of Genetics under the 

mentorship of Klaus Rajewsky. Tr. 204. He is currently a Director of the University of Alabama at Birmingham 

(“UAB”) in Immunology and Director of the T32 Training Program in Immunologic Diseases and Basic 

Immunology at UAB. Resp. Ex. A at 1. Dr. Schroeder also serves as an associate editor for the Journal of 

Immunology, for the Journal of Allergy and Clinical Immunology. Tr. 205; Resp. Ex. A at 1. He is also the editor 

of the textbook, Clinical Immunology: Principles and Practices. Tr. 205. Dr. Schroeder testified that has never 

testified before the Vaccine Court, but reviewed five cases for the respondent. Tr. 211. Dr. Schroeder also testified 

that he never treated any children with chronic urticaria. Tr. 219. In this case, respondent proffered and I accepted 

Dr. Schroeder as an expert in the area of immunology. Tr. 222.

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 2 of 25
3

Additionally, the same day, respondent filed his Rule 4(c) report recommending against 

compensation. Resp. Report (“Rept.”) (ECF No. 17). Respondent asserted that G.C.’s 

“symptom onset began in September 2013, on or about three months before her flu vaccination. 

G.C.’s symptom recurrence was relatively consistent both before and after vaccination....Thus, 

G.C.’s urticarial vasculitis has followed the normal course of the disease process, and the flu 

vaccination neither caused nor aggravated the disease course.” Resp. Rept. at 5. 

A Rule 5 status conference was held on February 24, 2016. The parties were ordered to 

submit additional expert reports. Scheduling Order (ECF No. 18). Petitioner submitted a 

supplemental expert report by Dr. Vera Byers on May 9, 2016. Pet. Ex. 12 (ECF No. 22). 

Respondent submitted a responsive report by Dr. Harry Schroeder on July 25, 2016. Resp. Ex. J 

(ECF NO. 24). 

After a status conference held on August 9, 2016, where the undersigned reviewed the 

additional expert reports, the parties agreed to proceed simultaneously with litigative risk 

settlement discussions and scheduling a date for an entitlement hearing. Scheduling Order (ECF 

No. 25). The parties engaged in unfruitful settlement discussions until December 16, 2016, at 

which point they reached an impasse and elected to proceed to an entitlement hearing scheduled 

for September 13, 2017. Resp. Status Report (ECF No. 32). Both parties briefed the case prior 

to the hearing. Pet. Prehearing Submissions filed June 1, 2017 (ECF No. 34); Resp. Prehearing 

Submissions filed June 28, 2017 (ECF No. 35). 

An entitlement hearing was held on September 13, 2017 and was continued on November 

8, 2017 in Washington, D.C. Petitioner, Ms. Brynn Contino offered fact testimony. Petitioner 

presented expert testimony from Dr. Vera Byers. Respondent presented expert testimony from 

Dr. Harry Schroeder via video conference. The parties submitted post hearing-briefs addressing 

key issues raised during the entitlement hearing and identifying the most relevant medical 

literature submitted. See Pet. Post Hearing Brief (“Pet. Brief”) (ECF No. 63); Resp. Post 

Hearing Brief (“Resp. Brief”) (ECF No. 64); and Pet. Post Hearing Rebuttal Brief (ECF No. 65). 

This matter is now ripe for adjudication. 

B. Summary of Relevant Facts

1. Medical Records from Birth to Influenza Vaccination on December 3, 2013

G.C. was born on November 6, 2010. Pet. Ex. 1 at 5. On December 23, 2010, G.C. 

presented to the Frederick Memorial Hospital emergency department with three days of 

coughing and congestion, no fevers, but had vomited twice. Pet. Ex. 5 at 62. She tested

negative for the flu virus, but positive for respiratory syncytial virus (“RSV”). Id. at 63. A deep 

nasal suction was performed with little improvement and she was placed on 1 Liter of oxygen, 

then increased to 2 liters. Pet. Ex. 1 at 175. G.C. was transported via helicopter to Johns 

Hopkins where she was admitted to the pediatric intensive care unit (“ICU”). Id. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 3 of 25
4

G.C. was admitted to Johns Hopkins from December 23-27, 2010. Pet. Ex. 3 at 6-10. 

Prior to discharge, she was weaned off oxygen support for 24 hours before she was sent home 

without any signs of respiratory distress. Id. at 7. 

The following year, G.C. was treated by Dr. James Lee on various occasions for coughs 

and upper respiratory infections. See Pet. Ex. 1(a) at 63, 127, 160. However, she continued 

receiving her scheduled childhood immunizations. Pet. Ex. 1(a) at 12 & Pet. Ex. 1(b) at 187. 

In February 2012, G.C. had a complete blood count test performed. Pet. Ex. 1(a) at 37. 

The test showed that her IgA, IgM and IgG subclasses were in normal range, but the total IgG 

was low. Pet. Ex. 5 at 130-135. Then on March 9, 2012, G.C. underwent a bilateral 

myringotomy and ventilation tube placement.

7

 Pet. Ex. 1(a) at 75; Pet. Ex. 5 at 144. 

On April 2, 2012, Dr. Samuel Rosenberg assessed G.C. for coughing and recurrent otitis

media. Pet. Ex. 1(a) at 81. Her physical exam was normal. Id. He noted that “her IgG was 

slightly reduced but the remainder of her immunoglobulins were normal and pneumococcal 

antibodies which showed elevation in several serotypes [are] indicative of good antibody 

response.” Id. After reviewing her history and performing a physical exam, Dr. Rosenberg 

recommended G.C. use an inhaler with corticosteroids to treat any asthma component to her 

cough. Id. He stated that “IgG level was slightly reduced, but I do not feel that this is 

representative of any significant immune system issue.” Id. Dr. Rosenberg also believed that the 

PE tubes placed in G.C.’s ears would “dramatically help with her recurrent respiratory 

symptoms.” Id. 

In the fall of 2012, G.C. has the right ventilation tube removed. Dr. Lee stated that “an

underlying acute otitis media with perforation was noted.” Pet. Ex. 1(a) at 76. Then in December 

2012, a second myringotomy with an adenoidectomy was performed. Pet. Ex. 1(a) at 75. 

In April 2013, G.C. was taken to see Dr. Lee twice for a cough without fever. Pet. Ex. 

1(a) at 102 & 104. He observed that her left ear tube appeared to be blocked by “opaque 

effusion,” but she did not have any rash or skin lesions. Id. at 102. He prescribed a course of 

amoxicillin twice a day for ten days. Id. at 103. 

Ms. Contino testified that in late August 2013, G.C. developed a rash. Transcript (“Tr.”) 

9. Ms. Contino stated that hives were located on G.C.’s armpit, bottom half of her thighs and the 

back of her knees. Id. She described these hives as “raised.” Tr. 10. Ms. Contino testified that 

she treated the hives with Benadryl and the rash went away within an hour. Tr. 12 & 35. She 

testified that a similar rash re-appeared on G.C. in September 2013. Tr. 9-10. Ms. Contino again 

gave G.C. Benadryl and the rash resolved within an hour. Tr. 12. She described that G.C. was 

“uncomfortable because they were itchy,” but the rash did not affect G.C’s play or eating. Tr. 11

& 35. 

 

7 A myringotomy and ventilation tube placement is a common procedure that surgically places small tubes in a 

child’s eardrum to help drain fluid out of the middle ear in order to reduce the risk of ear infections. Ear tubes are 

recommended for children who have persistent fluid buildup behind the eardrum. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 4 of 25
5

On September 13, 2013, G.C. was seen by Dr. Lee for assessment of a rash on her cheek 

that began two days prior to the office visit. Pet. Ex. 1(a) at 98. Dr. Lee observed “well defined 

pink patches, only slightly raised mostly along waistband, backs of thighs, ankles but also on 

abdomen, back of hands and cheek.” Id. He stated that “[G.C.] seems unaffected-well 

appearing/acting, not itching, rash is nontender, she was very cooperative with exam....seems to 

be more of an irritant dermatitis.” Id. Dr. Lee recommended Ms. Contino treat with Benadryl as 

necessary. Id. 

The next month, on October 3, 2013, G.C. was seen by allergist, Dr. Monika Korff, for 

hives. Id. at 69-70. Ms. Contino reported that 2-3 weeks ago G.C. “woke up one morning and 

was covered in hives....After taking the Benadryl for a day, the rash resolved.” Id. at 69. The 

rash reappeared three days later and was resolved by Benadryl. Id. Then, G.C. had another 

episode of rashes that resolved with Benadryl within 24 hours. Id. Dr. Korff performed a 

physical exam of G.C. and found that her conjunctivae were clear, allergic shiners absent and her 

lungs have good breath sounds without wheezing or rhonchi. Id. at 70. Dr. Korff assessed G.C. 

with dermatographic urticaria that “certainly explained the hives” and recommended treating the 

symptoms with Benadryl during episodes versus daily use of a long acting antihistamine as 

prophylaxis. Id. 

On October 21, 2013, G.C. saw Dr. Lee for constipation and difficult voiding. Pet. Ex. 

1(a) at 96. Dr. Lee observed G.C.’s skin as “pink, warm and dry.” Id. A urine sample was 

negative for protein. Id. Dr. Lee assessed G.C. with an abnormality of urination, noting G.C. 

was resistant on the toilet and opined that her voiding and constipation was attributable to toddler 

independence, rather than a medical issue. Id. at 97. A urinalysis was negative for protein in 

G.C.’s urine. Id. 

Dr. Lee saw G.C. on November 11, 2013 for complaints of an ongoing wet cough and 

congestion. Pet. Ex. 1(a) at 94. Upon physical exam, G.C. appeared “unhappy, but non-ill 

acting.” Id. Most notably, no skin rashes or lesions were observed. Id. Dr. Lee diagnosed G.C. 

with an acute upper respiratory infection of unspecified site and was given a ten-day course of 

amoxicillin. Id at 95. 

On December 3, 2013, G.C. received her third flu vaccine. Pet. Ex. 1(a) at 12. 

2. Medical History Post Flu Vaccination to Present

The family travelled from Maryland to Florida for a trip to Disney World on Saturday, 

December 7, 2013. Tr. 14. During the car trip, Ms. Contino noticed “smaller red blotchy 

rashes” on G.C. that “started on her stomach area.” Id. On December 9, 2013, while in the 

amusement park, G.C. refused to walk and complained that her legs really hurt. Tr. 15. Ms. 

Contino testified that G.C.’s hands, feet and lips began to swell. Id. She further testified that 

G.C. had between 60 to 80 bruises all over her body, including on her thighs, backside and 

stomach. That same night, Ms. Contino took G.C. to the emergency room of Florida Hospital. 

Tr. 21 & Pet. Ex. 5. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 5 of 25
6

G.C. was treated at the emergency department of Florida Hospital for hives, a fever of 

101 degrees Fahrenheit, bruising and swelling. Pet. Ex. 5 at 12, 16 & Pet. Ex. 2(a) at 7. The 

clinical impression of G.C. at the emergency room was G.C.’s symptoms were “most consistent 

with a viral exanthem” and she was given a steroid injection. Pet. Ex. 4 at 18. Upon discharge, 

she was given a prescription of prednisolone and Benadryl. Id. Ms. Contino testified that G.C.’s 

swelling went down after the steroid treatment at Florida Hospital, but the bruising remained. 

Tr. 25. 

Ms. Contino testified that this was the first time that G.C. had developed bruising 

associated with a rash. Tr. 23. She explained that G.C. experienced episodes of recurrent 

bruising and swelling in January 2014. Tr. 27. 

On February 3, 2014, G.C. was seen by pediatric allergist, Dr. Glenn Silber. Pet. Ex. 1(a) 

at 60. During that visit, Ms. Contino reported that G.C. continued to have rashes around three 

times a week that lasted about six hours and some swelling occured with cold exposure. Id. A 

physical exam revealed that G.C. had no rash and no dermatographism.

8

 Id. Ms. Contino 

testified that she showed Dr. Silber pictures she had taken of G.C. in Florida. Tr. 27. Dr. Silber

assessed G.C. with “probable vasculitis-doubt allergy with no pruritus” and recommended G.C. 

seek treatment from a pediatric rheumatologist. Id; Tr. 27. 

Ms. Contino testified that due to a four week wait for an appointment with a 

rheumatologist at Johns Hopkins, she drove G.C. to the Cleveland Clinic. Tr. 28. G.C. was seen 

by pediatric rheumatologist, Dr. Andrew Zeft, on February 12, 2014. Pet. Ex. 9 at 4. His 

physical exam of G.C. was relatively normal, but he ordered a complete blood count and 

immunoglobulin test. Id. Dr. Zeft opined that G.C.’s diagnosis was “most consistent with 

hemorrhagic edema of infancy triggered by influenza vaccination. Preceding urticaria may be 

idiopathic or potentially part of illness spectrum. No biopsy has been done on skin lesions to 

clarify leukocytoclastic vasculitis pathology. Presentation is not consistent with urticarial 

vasculitis.” Id. G.C.’s blood IgG, IgA and IgM levels were within normal limits.9 Id. at 13. 

When Dr. Zeft spoke to G.C.’s mother on February 13, 2014 to relay the test results, G.C. had 

apparently developed “new dependant bruises.” Pet. Ex. 9 at 16. Dr. Zeft recommended to 

recheck G.C.’s blood count and to consider dapsone.10

On February 20, 2014, G.C. was evaluated by rheumatologist, Dr. Sangeela Sule, at 

Johns Hopkins Division of Rheumatology. Pet. Ex. 2(a) at 4. Dr. Sule noted that two days after 

 

8 Dermatographism (also spelled, “dermagraphism”) is a type of physical urticaria in which moderately firm 

stroking or scratching of the skin with a dull instrument produces a wheal with a red flare on each side. Dorland’s

Illustrated Medical Dictionary 32nd ed. (2012) (hereinafter “Dorland’s”) at 499. 

9 Petitioner’s Pre-Hearing Brief states that G.C.’s IgG level was below normal and cites to Petitioner’s Exhibit 1(a) 

at 37. However, this reference is to an immunoglobulin test result from 2012. 

10 Dapsone is an antibacterial and antifungal medication administered orally for the treatment of dermatologic 

noninfectious inflammatory diseases. It was also used to treat leprosy and malaria. Golusin, Z. et al., What do we 

know about diaminodiphenylsulfone? 53 Med. Pregl. 369-72 (2000). Available at 

https://www.ncbi.nlm.nih.gov/pubmed/11214480 (accessed on August 22, 2019). 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 6 of 25
7

G.C. received the flu vaccine, she had hives, her legs and feet were swollen, and bruising 

appeared.11 Id. at 4. Dr. Sule developed a working diagnosis of “urticarial vasculitis” and 

referred G.C. to dermatology for a biopsy to confirm the tentative diagnosis of urticarial

vasculitis. Id. at 6. Additionally, Dr. Sule wanted a repeat urinalysis and recommended a renal 

ultrasound because of the two prior urine samples with elevated protein/creatinine (“pr/cr”)

ratios. Id. at 6. 

G.C. returned to Johns Hopkins on March 19, 2014 for an evaluation by pediatric 

nephrologist, Dr. Cozumel Pruette. Id. at 7. Dr. Pruette noted that the working diagnosis is 

“urticarial vasculitis” and there was concern that the proteinuria noted on previous urine samples 

may indicate possible renal involvement. Id. at 8. Dr. Pruette requested an additional first 

morning urine sample and a skin biopsy. Id. at 8. 

G.C. had a skin biopsy performed on her left arm on March 27, 2014 that confirmed the 

diagnosis of urticarial vasculitis. Id. at 9-10. The biopsy was positive for granular deposition of 

IgM and C3 in superficial derma blood vessels. Pet. Ex. 3 at 4. The test was negative for IgA, 

IgG and Fibrin. Id. Dr. Grant Anhalt noted that the “findings are seen in vasculitis.” Id. Dr. 

Max Fischer reviewed the biopsy results and changed G.C.’s diagnosis from “consistent with 

urticaria; negative for vasculitis” to “urticaria-like reaction pattern.” Id. at 5. 

On April 3, 2014, Dr. Sule called G.C.’s mother to confirm the biopsy findings and 

recommended G.C. begin 10 mg of prednisone and 15 mg Azathioprine12 daily. Id. at 10. On 

April 14, 2014, Dr. Puttgen saw G.C. to remove the suture. Dr. Puttgen stated that the 

differential diagnosis confirms vasculitis “which in the setting of the clinical presentation is 

consistent with urticarial vasculitis. The presentation in G.C. is somewhat unusual as the lesions 

come and go in less than 24 hours often, more typical of standard urticaria.” She continued by 

stating, “However, coupled with the complaints of leg pain and proteinuria, a more systemic 

process does fit.” Pet. Ex. 2(a) at 10. 

On April 25, 2014, Ms. Contino reported to Dr. Sule that G.C. was still experiencing 

intermittent hives associated with itching and pain. Pet. Ex. 2(a) at 11. Dr. Sule requested that 

the pharmacy at Johns Hopkins compound Azathioprine to a form that G.C. would be able to 

take, instead of tablets. Id. 

Drs. Sule, Puttgen and Pruette continued to manage and follow G.C.’s health between 

April and February 2015. See Pet. Ex. 2(a) at 9-18. G.C. continued to provide urine samples 

that showed abnormal urine pr/cr ratios, with individual numbers being within normal ranges. 

Id. at 12. 

 

11 Dr. Sule incorrectly states that G.C. received flu vaccine on December 5, 2015. G.C. received a flu vaccine on 

December 3, 2013. See Pet. Ex. 1(a) at 12. 

12 Azathioprine is an immunosuppressant drug that is used to treat dermatomyositis, systemic lupus erythematosus, 

inflammatory bowel disease, vasculitis and rheumatoid arthritis. Accessed at: https://www rheumatology.org/I-AmA/Patient-Caregiver/Treatments/Azathioprine-Imuran

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 7 of 25
8

On August 11, 2014, Dr. Pruette spoke with Ms. Contino regarding G.C.’s recent urine 

results showing increased pr/cr ratio. Id. at 13. Dr. Pruette recommended that G.C. remain on 

Imuran and prednisolone given that G.C.’s proteinuria is “relatively stable, kidney function 

remains stable and she is clinically doing well.” Id. Ms. Contino informed Dr. Pruttgen that 

G.C. was still experiencing leg pain and wanted to speak with Dr. Sule about decreasing the dose 

of prednisolone. Id. 

Ms. Contino testified that throughout the spring of 2014 and into the fall of 2014 G.C. 

was in constant pain. Tr. 37. G.C. would have pain primarily in her hip and legs, but 

occasionally in her arms. Tr. 38. G.C.’s rash symptoms were more intermittent, but would 

appear if she got very hot, however, G.C.’s pain was constant. Tr. 37. 

In September 2014, G.C. was seen by Dr. Jillian Kaskavage at Johns Hopkins Pediatric 

Rheumatology. Pet. Ex. 1(a) at 53. Ms. Contino reported that G.C. did not have any rash over 

the summer, but as the weather got cooler, G.C. had a rash appear at night, but was gone by the 

morning. Id. Additionally, G.C. was not complaining of any itchiness or pain. Id. Ms. Contino 

stated that G.C. experienced some pain in her lower extremities and observed G.C. grabbing her 

shins, however, no joint swelling was observed. Id. Dr. Kaskavage recommended G.C. continue 

on Azathioprine for at least one year at 2 mg daily due to the likely “renal involvement” and her 

continued abnormal urine pr/cr ratio. Id at 54. 

On December 17, 2014, Dr. Pruette saw G.C. for a follow-up appointment. Pet. Ex. 1(a) 

at 46. Dr. Pruette reported that G.C.’s proteinuria trend had been improving since the steroids 

were initiated. Id. Ms. Contino reported that G.C. still experienced leg pain, but no recent rash. 

Id. Dr. Pruette again assessed G.C. with proteinuria associated with underlying urticarial 

vasculitis. Id. She stated that G.C. responded favorably to the regimen of Azathioprine and 

steroids and that there was no need for a kidney biopsy at that time. Id. at 49. Dr. Pruette 

recommended that G.C. continue weaning her steroid dose and take MiraLAX to reduce her 

constipation. Id. 

From December 2014 through January 2015, G.C.’s doctors continued to wean her from 

prednisone and continued the course of Azathioprine at the current dose. Pet. Ex. 2(a) at 17. 

Then on February 16, 2015, G.C. experienced a recurrence of her urticarial vasculitis with 

multiple hives observed all over her body when she missed a dose of prednisone. Id. at 18. Dr. 

Sule recommended G.C. be treated with rituximab, 375 mg/m2 once a week for four weeks. Pet. 

Exs. 1(b) at 10 & Pet. Ex. 2 at 22-24. 

On March 25, 2015, G.C. was brought into the Johns Hopkins clinic presenting with a red 

rash on her face and abdomen but was alert and playful. Pet. Ex. 2 at 24. It was reported that 

again G.C. had missed a dose of prednisone. Id. Dr. Sule advised Ms. Contino to continue to 

give G.C. prednisone and to make a follow up appointment in a few weeks. Id. 

Dr. Mark Gorelik, pediatric rheumatologist, attended to G.C. on April 16, 2015. Pet. Ex. 

2(b) at 25. Ms. Contino reported that as G.C. was weaning from the steroids, a rash reappeared 

on her face, but no other symptoms returned. Id. Ms. Contino also reported that G.C. was 

slightly more tired lately and irritable since the wean. Id. Upon physical exam, Dr. Gorelik 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 8 of 25
9

observed a small 1 cm erythematous rash over the left check. Id. at 26. He noted that G.C.’s 

symptoms are improving on Azathioprine, but she had a borderline abnormal urine pr/cr ratio 

and suggested a follow up appointment in two months. Id. at 26. Ms. Contino called the clinic 

four days later, requesting to speak to the doctor and that G.C. was experiencing back pain over 

the past month. Id. at 26. Dr. Pruette followed up with Ms. Contino the following day, reporting 

that G.C.’s lab results were “good/stable,” and indicated that continuing the steroid wean would 

be appropriate. Id. at 27. 

On May 20, 2015, Dr. Pruette reported to Ms. Contino that G.C.’s lab results showed an 

increase in her pr/cr ratio from the previous month. Pet. Ex. 2(b) at 9. Ms. Contino reported that 

G.C. has “significant sun sensitivity from the steroids,” but informed Dr. Pruette there were “no 

other skin complaints.” Id. Dr. Pruette and Ms. Contino agreed to continue G.C. on the current 

prednisolone dose, check G.C.’s creatinine and CD19/CD20 counts to assess for ongoing effects 

of recent Rituximab course and follow proteinuria. Id. The lab results from May 21, 2015 show 

that G.C.’s CD19/CD20 lymphocyte levels were at zero. Id. at 45. 

On August 10, 2015, G.C. was seen by Dr. Lee for a fever of 102 degrees and a sore on 

her tongue. Pet. Ex. 10 at 6. Upon a physical exam, G.C. was irritable and excessively crying. 

Id. Dr. Lee described G.C. as “uncomfortable and acutely ill.” Id. at 11. Dr. Lee described a 

“yellow pustule [on] tip of tongue. Also, more classic cold sores inner mucus membrane and 

gingiva [is] generally inflamed.” Id. The next day, August 11, 2015 G.C. was hospitalized at 

Johns Hopkins for a rash that lasted 10 days, a fever of 102 degrees Fahrenheit and sores in her 

mouth for seven days. Pet. Ex. 6 at 4. G.C. was diagnosed with a viral exanthema and 

discharged on August 15, 2015.13 Id. 

Ms. Contino testified that G.C.’s mouth ulcers appeared monthly. Tr. 49. G.C. went 

back to Dr. Lee in October 2015 with sores under her tongue, decreased appetite and difficulty 

sleeping. Pet. Ex. 10 at 10. G.C. had been prescribed cephalexin on August 12, 2015. Id. A 

physical exam confirmed a single ulcer on G.C.’s inner cheek area. Id. at 12. Dr. Lee prescribed 

lidocaine to apply to the affected area of the mouth three times a day. Id. 

 Ms. Contino described the hives and bruising that appeared on G.C. after she received 

the flu shot as “smaller” with a “purplish tint to them,” in addition to “lots of swelling and pain 

in her legs.” Tr. 33. Petitioner submitted into evidence multiple color photographs of G.C. taken 

in December 2013 that depicted rashes and extensive bruising. See Pet. Ex. 18(a) Further, she 

testified that G.C.’s condition was much improved after receiving the rituximab treatment in 

March 2015. Tr. 38. However, G.C. continues to have mouth ulcers and continues to be on 

steroids because of her kidney involvement. Tr. 49-50; 340. She testified that G.C. is still on 

steroids and has been consistently since April 2014. Tr. 340. As recently as 2017, doctors at 

Kentucky Children’s Hospital are determining if G.C. can wean from the steroids because of 

concern that the steroids may be doing more harm to G.C.’s kidneys than the disease. Id. 

 

13 Both Dr. Byers and Dr. Schroeder make reference to G.C. being hospitalized on August 11, 2015, however, those 

records were never filed with the Court. Petitioner’s Exhibit 10 provides the lab results from G.C.’s hospitalization 

at that time but does not provide any further information. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 9 of 25
10

II. LEGAL STANDARD

The Vaccine Act provides two avenues for petitioners to receive compensation. A

petitioner may demonstrate a “Table” injury,14 or that a vaccine listed on the Vaccine Table was

the cause-in-fact of any injury. In the present case, petitioner does not establish that she has 

suffered a Table injury. 

To satisfy the burden of proving causation-in-fact, petitioner must “show by preponderant 

evidence that the vaccination brought about the injury by providing 1) a medical theory 

connecting the vaccination and injury; 2) a logical sequence of cause and effect showing that the 

vaccination was the reason for the injury; and 3) a showing of proximate temporal relationship 

between vaccination and injury.” Althen v. Sec’y of Health & Human Servs., 418 F. 3d 1274, 

1278 (Fed. Cir. 2005). Petitioner’s must establish each Althen prong by the preponderance of the 

evidence. Caves v. Sec’y of Health & Human Servs., 100 Fed. Cl. 119, 132 (2011), aff. per 

curiam, 463 Fed. Appx. 932 (Fed. Cir. 2012).

The preponderance of the evidence standard requires a petitioner to demonstrate that it is 

“more likely than not” that the vaccine caused her injury. Moberly v. Sec’y of Health & Human 

Servs., 592 F.3d 1315, 1322 n.2 (Fed. Cir. 2010). Proof of medical certainty is not required. 

Bunting v. Sec’y of Health & Human Servs., 931 F.2d 867, 873 (Fed. Cir. 1991). In particular, a 

petitioner must demonstrate that the vaccine was “not only [a] but for cause of the injury but also 

a substantial factor in bringing about the injury.” Moberly, 592 F.3d at 1321 (quoting Shyface v. 

Sec’y of Health & Human Servs., 135 F.3d 1344, 1352-53 (Fed. Cir. 1999); Pafford v. Sec’y of 

Health and Human Servs., 451 F.3d 1352, 1355 (Fed. Cir. 2006). Causation is determined on a 

case-by-case basis, with “no hard and fast per se scientific or medical rules.” Knudsen v. Sec’y of 

Health & Human Servs., 35 F.3d 543, 548 (Fed. Cir. 1994). A fact-finder may rely upon 

“circumstantial evidence” which the court found to be consistent with the “system created by 

Congress, in which close calls regarding causation are resolved in favor of injured claimants.” 

Althen, 418 F. 3d at 1280. 

Establishing a sound and reliable medical theory connecting the vaccine to the injury 

often requires petitioners to present expert testimony in support of his or her claim. Lampe v. 

Sec’y of Health & Human Servs., 219 F.3d 1357, 1361 (Fed. Cir. 2000). Expert testimony in the 

Vaccine Program is usually evaluated according to the factors set forth in Daubert v. Merrell 

Dow Pharm., Inc., 509 U.S. 579, 594-96 (1993); see also Cedillo, 617 F.3d at 1339 (citing 

Terran v. Sec’y of Health & Human Servs., 195 F.3d 1302, 1316 (Fed. Cir. 1999). Thus, for 

Vaccine Act claims, a “special master is entitled to require some indicia of reliability to support 

the assertion of the expert witness.” Moberly at 1324. The Daubert factors are used in weighing 

the reliability of scientific evidence proffered. Davis v. Sec’y of Health & Human Servs., 94 Fed. 

Cl. 53, 66-67 (2010). Where both sides offer expert testimony, a special master’s decision may 

be “based on the credibility of the experts and the relative persuasiveness of their competing 

theories.” Broekelschen v. Sec’y of Health & Human Servs., 219 F.3d 1339, 1347 (Fed. Cir. 

2010) (citing Lampe v. Sec’y of Health & Human Servs., 219 F.3d 1357, 1362 (Fed. Cir. 2000). 

 

14 A “Table” injury is an injury listed on the Vaccine Injury Table, 42 U.S.C. § 100.3, corresponding to the vaccine 

received within the time-frame specified. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 10 of 25
11

Once a petitioner has proven causation by preponderant evidence, the burden shifts to 

respondent to show by a preponderance of the evidence that the injury is due to factors unrelated 

to the administration of the vaccine. Deribeaux ex rel. Deribeaux v. Sec’y of Health & Human 

Servs., 717 F.3d 1363, 1367 (Fed. Cir. 2013) (citing § 13(a)(1)(B)). Respondent has the burden 

of demonstrating that “a factor unrelated to the vaccination is the more likely or principal cause 

of injury alleged. Such a showing establishes that the factor unrelated, not the vaccination, was 

‘principally responsible’ for the injury. If the evidence or alternative cause is seen in equipoise, 

then the government has failed in its burden of persuasion and compensation must be awarded. 

Knudsen, 35 F.3d at 551. 

III. DISCUSSION

A. Diagnosis 

The medical records establish that G.C. has been diagnosed with urticarial vasculitis. 

Pet. Ex. 2(a) at 10. The parties do not dispute G.C.’s ultimate diagnosis, but debate when the 

autoimmune condition began. 

Respondent argued that G.C’s symptoms of manifested in the late summer or early fall of 

2013, three months prior to the vaccination. Resp. Ex. A at 8; Resp. Brief at 8. Petitioner argued 

that G.C.’s rash and hives that appeared in the late summer/early fall of 2013 were part of a 

separate allergic response and that she did not develop symptoms associated with her 

autoimmune urticarial vasculitis until after the December 3, 2013 flu vaccination. 

1. Acute Urticaria

Urticaria, better known as “hives,” is a common dermatologic condition that typically 

presents with intensely pruritic, well-circumscribed, raised wheals ranging from several 

millimeters to several centimeters or larger in size.15 Urticaria is historically divided into acute 

and chronic disease, dependent on the disease duration.16 Pet. Ex. 16(f) at 2. Urticaria that recurs 

within a period of less than six week is classified as acute; chronic urticaria becomes chronic if 

disease activity continues for six weeks or longer. Id. 

According to Nelson’s Pediatric Textbook, acute urticaria is often caused by an allergic 

IgE-mediated reaction.17 Pet. Ex. 16(t) at 1. However, acute urticaria can also result from nonIgE mediated stimulation of mast cells caused by viral agents including Epstein-Barr and 

hepatitis B or physical stimuli, such as a change in temperature. Id. at 1-2. 

 

15 Paul Schaffer, Acute and Chronic Urticaria: Evaluation and Treatment, 95 Am. Family Physician 11 (June 1, 

2017), https://www.aafp.org/afp/2017/0601/p717.html

16 Clive Grattan, The Urticarias: pathophysiology and management, 12 Clinical Medicine 2, 164-167 (2012). [Pet. 

Ex. 16(f)]. 

17 Donald Y.M. Leung and Stephen C. Dreskin, Chapter 147: Urticaria (Hives) and Angioedema, 18th ed. Nelson’s 

Pediatrics Textbook, 979-82 [Pet. Ex. 16(t)]. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 11 of 25
12

Allergic acute urticaria is a “self-limited process that occurs when an allergen activates 

mast cells in the skin.” Id. As explained in the Grattan article, “the mast cell plays a central role 

in most patterns of urticaria by releasing histamine which, in turn, acts on capillaries and 

cutaneous nerve endings to elicit the characteristic itchy red wheals.” Pet. Ex. 16(f) at 3. The 

stimulus for mast cell degranulation may be immunological. Id; Pet. Ex. 6 at 5; Pet. Ex. 8(c) at 

1

18; and Pet. Ex. 17(e) at 1.19

 The cross-linking of two or more adjacent allergen-specific 

immunoglobulin (“IgE”) molecules bound to the high affinity IgE receptor (“FcεRI”) will initiate 

a series of calcium-dependent intracellular signaling events leading to incomplete degranulation 

in allergic urticaria. Pet. Ex. 16(f) at 3. This leads to the release of histamine, leukotrienes, 

platelet activating factor (PAF), enzymes such as tryptase and chymase, cytokines and 

chemokines. Pet. Ex. 16(l) at 2.

20

 

Acute urticaria typically resolves within twelve hours and responds well to 

antihistamines. Pet. Ex. 6 at 5; Pet. Ex. 8(c) at 13; Pet. Ex. 16(f) at 1; Pet. Ex. 16(t) at 4. 

2. Chronic Urticaria

Chronic urticaria is diagnosed when symptoms have been continuously or intermittently 

present for six weeks. See Pet. Ex 8(j)21; Pet. Ex. 16(f); Pet. Ex. 17(e). Critical to the definition 

of chronic urticaria in the medical articles submitted is the duration of the lesions. Najib and 

Sheikh define chronic urticaria as “symptoms have been continuously or intermittently present 

for at least six weeks.” Pet. Ex. 8(j) at 1 (emphasis added). Chang, et. al, defines chronic 

spontaneous urticaria as the presentation of itchy wheal-and-flare skin reactions, angioedema or 

both for a period of greater than six weeks.22 Pet. Ex. 8(f) (emphasis added). Grattan states that 

urticarial activity may be active for a few weeks, settle for another few weeks or months, then 

unpredictably return to what it was previously. Id. 

Causes for chronic urticaria can be physical, allergic, hereditary or autoimmune. See 

Resp. Ex. A at 9; Pet. Ex. 6 at 5; Pet. Ex. 17(e) at 2; and Pet. Ex. 16(f) at 3. Between 30 and 50 

percent of cases of chronic urticaria are autoimmune in nature. Pet. Ex. 8(j) at 1. 

Both the experts agree that chronic urticaria resulting from an autoimmune disorder are 

due to the development of autoantibodies directed against either the FcεRI receptor or the IgE on 

mast cells and basophils. Resp. Ex. A at 9; Pet. Ex. 6 at 6. The autoantibodies directed against 

 

18 Katherine Altman and Christopher Chang, Pathogenic Intracellular and Autoimmune mechanisms in Urticaria 

and Angioedema, 45 Clinical Rev. Allerg. Immunol, 47-62 (2013) [Pet. Ex. 8(c)]. 

19 Gregory M. Metz and John S. Sundy, Allergy and immunology problems and musculoskeletal specialists, 

Rheumatology Network (May 7, 2009), http://www rheumatologynetwork.com [Pet. Ex. 17(e)]. 

20 Allen P. Kaplan, MD, Urticaria and Angioedema: Synopsis, World Allergy Organizations (2014) [Pet. Ex. 16(l)].

21 Umer Najib M.D. and Javed Sheikh, M.D., The Spectrum of Chronic Urticaria, 30 Allergy Asthma Proc., 1-10 

(2009) [Pet. Ex. 8(j)].

22 Tse Wen Chang, Ph.D, et.al., The potential pharmacologic mechanisms of omalizumab in patients with chronic 

spontaneous urticaria, 135(2) J. Allergy Clin. Immunol., 337-342 (2014) [Pet. Ex. 8(f)]. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 12 of 25
13

the IgE binding site on mast cells cause the mast cells to spontaneously degranulate in absence of 

allergens. Pet. Ex. 6 at 6; Pet. Ex. 16(f) at 3 & Pet. Ex. 17(e) at 2. According to the Metz article, 

approximately 40 percent of patients with chronic idiopathic urticaria have autoantibodies

directed against a subunit of the FcεRI or to cell-surface IgE that may lead to IgE receptor crosslinking, leading to cell activation. Pet. Ex. 17(e) at 2. 

The Altman article also indicates that the dysregulation of intracellular signaling 

pathways involving Syk, SHIP-1 or SHIP-2 in basophils and mast cells may be another 

autoimmune mechanism of chronic urticaria. Pet. Ex. 8(c) at 1, 5; Resp. Ex. A at 9. SHIP-1 and 

SHIP-2 are negative regulatory molecules that can dephosphorylate positive signaling mediators 

and control the activation and degranulation of mast cells and basophils, ultimately 

downregulating mast cell and basophil activation. Id. Syk on the other hand promotes mast cell 

degranulation. Id. Altman cited a study in which the mast cells from patients with chronic 

urticaria with an elevated level of histamine release after stimulation were found to have lower 

levels of SHIP-2 and increased levels of Syk. Pet. Ex. 8(c) at 4-5. Dr. Schroeder also endorsed 

this mechanism for development of chronic urticaria. Resp. Ex. A at 9. 

The first line of treatment for chronic urticaria are first or second generation H1-receptor

antagonists (antihistamines). Pet. Ex. 8(j) at 6. These drugs include Benadryl (first generation), 

Zyrtec (second generation) or Claritin (second generation). Id. at 6-7. If the patient’s symptoms 

do not respond to the H1-antagonists alone, then corticosteroids can be considered. Id. at 7; Pet. 

Ex. 16(t) at 4. In autoimmune chronic urticaria that is unresponsive to first-and-second line 

treatments immunomodulatory drugs may be used, such as cyclosporin, Dapsone, and

intravenous immune globulin. Pet. Ex. 8(h) at 2.

23

3. Urticarial Vasculitis

Urticarial vasculitis is a subgroup of the larger vasculitides disorders characterized by 

inflammation of blood vessels leading to tissue or end-organ injury.24 Resp. Ex. I at 2. Vasculitis 

may be triggered by an infectious agent or may be a complication of primary autoimmune 

dysregulation and/or immunosuppressive therapy, among other disorders. Id. Urticarial 

vasculitis primarily affects the small vessels of the skin.

25

 Pet. Ex. 16(q) at 2. A small number 

of individuals with chronic urticaria may have urticarial vasculitis.26 Overall, vasculitis in 

children is rare. Resp. Ex. I at 2. Patients with vasculitis and urticaria are considered a subpopulation of chronic spontaneous urticaria. Pet. Ex. 16(l) at 2. According to the Najib article, 

 

23 Marcus Mauer et. al, Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria, 386 N. Eng. 

J. Med., 924-35 (2013) [Pet. Ex. 8(h)].

24 Caterina Bonetto et al., Vasculitis as an adverse event following immunization-Systemic literature review, Vaccine 

2015 [Resp. Ex. I]. 

25 What is Urticarial Vasculitis? Vasculitis Foundation, accessed on August 13, 2019: 

https://www.vasculitisfoundation.org/education/forms/urticarial-vasculitis/

26 S. J. Deacock, An Approach to the patient with urticaria, Clin. Exp. Immunol (2008); doi: 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2492902/#b71

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 13 of 25
14

“urticarial vasculitis is considered to be an extreme form of chronic urticaria.” Pet. Ex. 8(j) at 4. 

Non-blanching lesions can last for more than 24 hours and leave residual marks. Id. Vasculitic 

lesions have different features from typical urticaria, including a burning or painful sensation 

instead of pruritus, abdominal pain and fever. Pet. Ex. 17(e) at 6. 

According to the article by Jennette and Falk,

27 “urticaria can be a manifestation of smallvessel vasculitis, especially when there is an immune-complex deposition with extensive 

complement activation.” Pet. Ex. 16(k) at 6. The article also distinguishes urticarial vasculitis 

from allergic urticaria, stating, “vasculitic urticaria lasts for more than a day, may evolve into 

purpuric lesions and may be accompanied by hypocomplementemia.” Id. The article by Russell 

and Gibson28 clarifies that hypocomplementemic urticarial vasculitis (“HUV”) is frequently

associated with systemic lupus erythematosus (“SLE”) like systemic findings, often with 

multiorgan involvement. Pet. Ex. 16(w) at 3. 

A skin biopsy is performed to confirm vasculitis. Id. A predominantly dermal interstitial 

neutrophilic infiltrate has been shown to be more frequent in HUV. Id. at 5. Skin biopsies from 

patients with immune-complex mediated vasculitis reveal significant neutrophilic infiltrates.29 

Pet. Ex. 16(q) at 5. Immunofluorescence evaluation may be used because of the difficulty 

identifying a lesion of the ideal age. Id. Russell and Gibson note that “especially in patients 

with widespread, recurrent crops of palpable purpura, knowledge of the age of lesions can be 

extremely difficult.” Id. When evaluating the vasculitic lesion by immunofluorescence, 

prominent IgM can be suggestive of SLE. Id. at 6. Strong deposition of C3 in either blood 

vessels or the basement membrane zone is more suggestive of HUV. Id. at 5. 

The treatment for vasculitis depends on the severity of the symptoms of the patient. Pet. 

Ex. 16(w) at 6. The use of anti-inflammatory drugs and antihistamines are used to treat 

symptomatic complaints. Id. However, for recurrent or chronic symptoms utilizing immune 

suppressant medication, like azathioprine or cyclosporine may be effective. Id. Azathioprine has 

been shown to be effective in preventing clinical recurrence, either on its own or with low-dose 

continued prednisone. Id. at 7. 

In this case, G.C. had a skin biopsy performed on March 27, 2014 that confirmed 

vasculitis. Pet. Ex. 3 at 2. The biopsy demonstrated “subtle dermal edema with a sparse 

perivascular and interstitial infiltrate consisting of neutrophils, eosinophils and lymphocytes, 

with a mild predominance of neutrophils. Pet. Ex. 3 at 5. Direct immunofluorescence revealed 

granular deposition of IgM and C3 in superficial dermal blood vessels. Id. at 4. Dr. Sule began 

treating G.C. with 10 mg of prednisone and 15 mg of azathioprine on April 3, 3014 after 

reviewing the pathology report from the biopsy. Pet. Ex. 2 at 10. 

 

27 J. Charles Jennette, M.D. and Ronald J. Falk, M.D., Small-Vessel Vasculitis, 337 New England Jour. Of Medicine, 

1512-1517 (1997) [Pet. Ex. 16(k)].

28 James P. Russell, M.D. and Lawrence E. Gibson, M.D., Primary cutaneous small vessel vasculitis: approach to 

diagnosis and treatment, 45 International Journal of Dermatology, 3-13 (2006) [Pet. Ex. 16(w)]. 

29 Durga P. Misra and Vikas Agarwal, Innate immune cells in the pathogenesis of primary systemic vasculitis, 36 

Rheumatol Int. 169-182 (2016) [Pet. Ex. 16(q)].

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 14 of 25
15

Additionally, G.C. was referred to the Harriet Lane Kidney Center for evaluation of 

proteinuria.30 Dr. Pruette stated that there was a concern for possible kidney involvement. Pet. 

Ex. 3 at 5. Dr. Pruette noted that kidney involvement is rare, but has been “described as more 

severe when noted in children with urticarial vasculitis.” Id. 

B. Classification of G.C.’s Condition Before and After the Vaccination

The petitioner contended that the hives G.C. experienced in August and September 2013 

were “merely allergic in nature.” Pet. Brief at 23. Petitioner argued that the symptoms and 

treatment of G.C.’s hives in the fall of 2013 differed dramatically from the symptoms and 

treatment of G.C.’s skin condition that began occurring five days after she received the flu 

vaccination. Id. Respondent argued that G.C.’s post-vaccination diagnosis was the natural 

progression of her pre-vaccination symptomology and disease process. Resp. Brief at 14. 

Respondent stated that “...it is less important for the Special Master to try to define what type of 

urticaria G.C. had before the vaccination. The important point is that [G.C] had urticaria before 

the vaccination, and was later diagnosed with [chronic urticaria] and [urticarial vasculitis] after 

vaccination.” Id. 

The respondent is asking the Court to simply accept his assertion that G.C.’s prevaccination symptoms were the beginning of her urticarial vasculitis without further inquiry as to 

the differences between the nature, duration and treatment of G.C.’s symptoms before and after 

the vaccination. Yet, answering the question as to what type of urticaria G.C. had prior to the 

vaccination is critical to resolving this case, particularly when the difference is distinguishing 

between a common skin condition, hives, and an autoimmune condition, urticarial vasculitis. 

Dr. Byer’s opined that the intermittent hives G.C. experienced four months prior to the 

vaccination were “consistent with an allergic, IgE mediated condition.” Dr. Byers stated that the 

hives were “mild,” “only lasted one day at a time,” and, “responded to Benadryl.” Pet. Ex. 6 at 

6; Pet. Ex. 12 at 2. 

Dr. Byers testified that in the summer of 2013, G.C.’s urticaria met the classification for 

acute urticaria. Tr. 75. She stated that the three episodes of hives G.C. had prior to the vaccine 

were readily treated within hours with Benadryl which resolved the rash. Tr. 78; 136. Dr. Byers 

explained that hives are “basically limited to the epidermis, which is the top layer of 

skin...primarily caused by vasodilation.” Id. G.C.’s hives prior to the vaccine were mild and 

required no treatment beside Benadryl. Pet. Ex. 12 at 2. There was no edema or bruising. Id. 

Further, Dr. Byers observed that the location of the hives prior to the vaccine was in G.C.’s 

armpit, back of the legs and the stomach and the rash was not accompanied by edema. Tr. 80 & 

135. There are no other medical records that document any skin lesion, rash or hives between 

mid-September 2013 and the December 9, 2013 emergency room visit at Florida Hospital. 

Dr. Schroeder, on the other hand, opined that the hives G.C. experienced in the fall of 

2013 was the first appearance of chronic urticaria, G.C.’s autoimmune condition and it naturally 

progressed after the vaccination. Resp. Ex. A at 8, 10; Resp. Ex. J at 3-4. In responding to Dr. 

 

30 Proteinuria is excessive serum proteins in the urine, such as in renal disease, after strenuous exercise, and with 

dehydration. Dorland’s at 1535. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 15 of 25
16

Byers’ opinion that G.C.’s initial hives was acute urticaria cased by allergens, Dr. Schroeder 

stated, “Most importantly, with the exception of the febrile episode five days post vaccination 

that resolved within a week and which her physicians judged due to a viral exanthem, the rash 

which was the most visible manifestation of her vasculitis was the same prior to and after the 

administration of the influenza vaccine.” Resp. Ex. A at 11 (emphasis added). After reviewing 

the medical records, Dr. Schroeder concluded, “The records indicate that the skin manifestations 

occurred every two to three weeks before the vaccination and every two to three weeks after the 

vaccination.” Id. at 12. 

A review of the medical records, the expert testimony and medical literature, the 

persuasive testimony of Ms. Contino, and the photographic evidence petitioner submitted into

the record, demonstrates that G.C.’s condition prior to the vaccination and after the vaccination 

were distinctly different in presentation and symptomology. 

When G.C. was evaluated at her pediatrician’s office for a rash on September 13, 2013, 

G.C.’s skin condition was described as “well defined pink patches, only sl (slightly) raised 

mostly along waistband, backs of both thighs, ankles, but also on abdomen, back of hands and 

cheek (R).” Pet. Ex. 1(a) at 98. Dr. Lee noted that “G.C. seems unaffected-well 

appearing/acting, not itching, rash is nontender, she was cooperative with exam.” Id. Dr. Lee 

recommended Benadryl and an oatmeal bath as necessary. Id. G.C. saw Dr. Lee again on 

October 21, 2013 for unspecified constipation. Id. at 97. Her skin appeared “pink, warm, dry,” 

and there was no mention of a rash. Id. In the medical record from the visit with Dr. Korff on 

October 3, 2014 states, “About 2-3 weeks ago [G.C.] woke up one more morning and was 

covered in hives. She was seen by the pediatrician and placed on Benadryl. After taking the 

Benadryl for a day, the rash resolved. Then 3 days later the hives reappeared and Benadryl again 

helped. She had another episode after that which again resolved with Benadryl.” Pet. Ex. 1 at 

69-70. Dr. Korff did not report any active hives, lesions or other skin markings on her physical 

exam of G.C., aside from noting that G.C. is dermatographic. Id. at 70. Dr. Korff diagnosed 

G.C. with dermatographic urticaria and recommended symptomatic treatment with Benadryl 

during episodes. Id. at 70. Ms. Contino testified that G.C. did not experience any additional 

hives in September, October, November and in December prior to the flu vaccine. Tr. 336. 

The medical records are also consistent with Ms. Contino’s testimony. She described the 

hives that appeared in the fall of 2013 as “red and large,” and “covered a very large area on 

[G.C.’s] armpit, on her stomach and the backs of her legs.” Tr. 8. Ms. Contino testified that 

based on the recommendation of the pediatrician, she gave G.C. Benadryl and the hives “went

away within an hour.” Tr. 12. She testified that between late August and early September 2013, 

she treated G.C.’s hives with Benadryl and they resolved within an hour each time. Id. Ms. 

Contino also testified that G.C.’s last episode of hives in the fall of 2013 occurred in late 

September. Tr. 13. She testified that G.C. did not experience another episode of hives from late 

September to the time of vaccination on December 3, 2013. Id. 

After the vaccination, Ms. Contino’s description of G.C.’s hives changed dramatically. 

She testified that five days after the flu vaccination small red spots began to appear on G.C. Tr. 

14, 337. Then G.C.’s legs began to swell and her feet began to turn purple. Tr. 337. G.C. 

refused to walk while in Disney World. Id. Ms. Contino stated that the rashes began to spread to 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 16 of 25
17

her cheeks and up and down her legs. Tr. 15. Additionally, G.C. developed “60-80 bruises all 

over her body,” that appeared purplish. Tr. 16. Ms. Contino rushed G.C. to the emergency room 

on the evening of December 9th where she was given steroids and Benadryl. Tr. 343. 

When the family returned home from Florida, the purplish bruises, swelling in her hands 

and feet and joint pain would return “a couple of times a week.” Tr. 342. Ms. Contino testified 

that G.C. did not have any symptoms of pain, swelling, or bruising associated with the hives that 

appeared in September. Tr. 342, 344. She stated that beginning with the event in Florida G.C’s 

leg and joint pain was so bad that she would only lay in bed and cry. Tr. 338. Ms. Contino 

testified that G.C.’s symptoms of joint pain and swelling were so serious that she drove all the 

way from Maryland to the Cleveland Clinic to get G.C. seen as soon as possible. Id. It was not 

until a skin biopsy was performed on March 27, 2014 that G.C. was definitively diagnosed with 

urticarial vasculitis.31 See Pet. Ex. 3 at 1. 

Dr. Schroeder was focused solely on the recurrence of G.C.’s hives and did not 

acknowledge that the post-vaccine hives were accompanied by joint pain, bruising and swelling 

and kidney issues that began in December and continuing thereafter. His opinion that “the rash

which was the most visible manifestation of [G.C.’s] vasculitis was the same to and after the 

administration of influenza vaccine,” is contradicted by both the medical evidence and the 

convincing testimony of Ms. Contino. 

When G.C. was treated for hives in the fall of 2013, the medical records did not include 

any notation that G.C. was experiencing any of the symptoms associated with vasculitis. It was 

only after the vaccination did G.C. begin to complain about joint pain, experience significant 

swelling and develop bruises. See Pet. Ex. 3 at 4,7; Pet. Ex. 9 at 16. Both the medical records 

and Mrs. Contino’s testimony are clear that the rash G.C. experienced in the fall of 2013 

responded almost immediately to Benadryl. See Pet. Ex. 1(a) at 69, 98; Tr. 335.

During the hearing, Dr. Schroeder acknowledged that some of the symptoms G.C. 

experienced in the fall of 2013 were different than the symptoms that presented after the 

vaccination. He conceded that G.C. did not have any leg or feet swelling in September 2013, as 

she did experience on December 9, 2013. Tr. 301. Dr. Schroeder also conceded that G.C. did 

not experience bruising in September or early October, as she did after the vaccination. Tr. 302. 

In fact, Dr. Schroeder stated, “the symptomatology that [G.C] had in December was different 

then the symptomatology that she had before and after. I don’t recall there being any reports in 

the case...when she was having the active vasculitis where she had difficulty walking...general 

swelling, et cetera, or that she had a fever. Everything was focused on her skin.” Tr. 308

(emphasis added). When questioned whether he agreed if the symptoms of pain, history of 

bruising, history of swelling was suggestive of something different than urticaria, Dr. Schroeder 

stated, “Yes. Yes. That’s what I said. There’s a difference about what happened in December 

versus what happened before and after. I agree with that.” Tr. 311-12. However, Dr. Schroeder 

attempted to distinguish the symptoms of bruising, joint pain and swelling that G.C. experienced 

in December as unique, one-time event caused by a virus. 

 

31 A biopsy for this condition can only be done on an active lesion and because of the episodic nature of the disease 

and the difficulty in scheduling an immediate appointment at Johns Hopkins when a flare occurred the biopsy was 

not done until March 27, even though Dr. Sule’s working diagnosis was urticarial vasculitis before that time.

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 17 of 25
18

As explained above, vasculitis is often accompanied by joint pain or swelling and can 

have renal involvement. The record well establishes that G.C.’s symptoms of joint swelling, 

bruising and pain, in addition to the hives, continued regularly until she was diagnosed with 

urticarial vasculitis and treated accordingly. The newly appearing vasculitic symptoms of

bruising, swelling and joint pain was the reason that Ms. Contino drove G.C. from Maryland to 

the Cleveland Clinic. It was the accompanying symptoms of joint pain, swelling, and bruising 

that caused Dr. Silber and the doctors at Johns Hopkins to suspect vasculitis and order a biopsy 

to confirm the diagnosis. See Pet. Ex. 1(a) at 60; Pet. Ex. 2(a) at 6. 

Based on the medical records, the opinions of the experts and the testimony of Ms. 

Contino, I conclude that it is more likely than not that the hives G.C. experienced in the fall of 

2013 should be classified as an allergic IgE-mediated response and what she experienced five 

days post-vaccination was the initial presentation of G.C.’s autoimmune urticarial vasculitis

which continued thereafter. 

A. Althen Prong One: Medical Theory

1. Legal Standard

Under Althen prong one, the causation theory must relate to the injury alleged. Thus, a 

petitioner must provide a “reputable” medical or scientific explanation, demonstrating that the 

vaccine received can cause the type of injury alleged. Pafford, 451 F.3d at 1355-56 (Fed. Cir. 

2006). The theory need only be “legally probable, not medically or scientifically certain.” Id. at 

1380 (quoting Knudesn, 35 F.3d at 548). However, the theory still must be based on a “sound 

and reliable medical or scientific explanation.” Knudsen at 548. The Federal Circuit explained 

in Althen that “while [that petitioner’s claim] involves the possible link between [tetanus toxoid] 

vaccination and central nervous system injury, a sequence hitherto unproven in medicine, the 

purpose of the Vaccine Act’s preponderance standard is to allow the finding of causation in a 

field bereft of complete and direct proof of how vaccines affect the human body.” Althen, 418 

F.3d at 1280 (emphasis added). 

2. Discussion

The experts agree that the causes of chronic urticaria can be autoimmune. Pet. Ex. 6 at 5; 

Resp. Ex. A at 9. Petitioner submitted an article by Altman and Chang titled, Pathogenic 

Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema, which Dr. Schroeder 

stated provided “a good review of our current understanding of the pathogenesis of urticaria.” 

Resp. Ex. A at 9. Additionally, both the experts agree that the G.C.’s underlying urticarial 

vasculitis is the product of an autoimmune process. Resp. Ex. A at 12; Pet. Ex. 6 at 8; and Pet. 

Ex. 12 at 2. The main disagreement between the experts is the nature of the urticaria that G.C. 

experienced prior to the vaccination and the urticaria G.C. experienced post-vaccination. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 18 of 25
19

a. Experts’ Opinion on Causation

Dr. Byers opined that through bystander activation the flu vaccine caused G.C.’s 

urticarial vasculitis which initially appeared after the flu vaccination. Pet. Ex. 6 at 8; Tr. 118-119. 

The Agmon-Levin32 article, which Dr. Byers’ quoted in her first report and during hearing 

testimony explains bystander activation:

“Bystander activation is a situation where enhanced cytokine production promotes the 

expansion of autoreactive T cells, whose prior number has been insufficient to produce an 

overt disease. In the case of polyclonal activation of B cells, the increased B cell 

proliferation, antibody production and the generation of circulating immune complexes 

may eventually damage self-tissues.”

Pet. Ex. 8(b) at 2; Tr. 118-119. Dr. Byers also submitted an article by Fujinami et al33., that 

described the role of bystander activation in the production of autoimmune disease. Pet. Ex. 

16(e). The article describes the stimulation of antigen presenting cells that could potentially 

activate pre-primed autoreactive T-cells which then initiate autoimmune disease by bystander 

activation. Pet Ex 16(e) at 2.

Dr. Byers testified that every individual is born with dormant autoreactive immune cells. 

Tr. 123; Pet. Ex. 23 at 4. She testified that the body contains anti-self lymphocytes, including 

CD4 T cells, CD8 T cells, and B cells that are slowly replicating, but under control of Tregulatory cells. Tr. 119. She explained that these cells can be activated by the innate immune 

systems response to an antigen. Tr. 122-124. When the cells of the innate immune system are 

activated they react with the antigen, but also release cytokines. Id. Macrophages and dendritic 

cells first respond to an incoming antigen and produce a blast of cytokines. Pet. Ex. 23 at 9. The 

enhanced cytokine production activate the adaptive immune system’s B and T cells that are 

antigen specific. Pet. Ex. 23 at 6, 8; Tr. 124-127. In addition to the antigen-specific T and B 

cells, the dormant autoreactive T and B cells are also activated and may start to generate 

autoantibodies. Pet. Ex. 23 at 8; Tr. 126-127. 

Dr. Byers referred to an article by van Alst et al.34 to further explain that in bystander 

activation, T cells unrelated to an antigen presented can be activated without classical T-cell 

receptor (TCR) ligation, but rather via cytokines like IL-2 as a result of the excessive activation 

of cells during the classical response. Pet. Ex. 17(a); Tr. 130-31. 

Dr. Byers explained that the third flu vaccine G.C. received on December 3, 3013 caused 

a sudden inflammatory response in her skin by the release of pro-inflammatory cytokines. Pet. 

Ex. 6 at 8. She explained the flu vaccination stimulated the innate immune system in G.C., 

 

32 Nancy Agmon-Levin et. al., Influenza Vaccine and Autoimmunity, 11 IMAJ 183-185 (2009) [Pet. Ex. 8(b)].

33 Robert S. Fujinami et al., Molecular Mimicry, bystander activation, or viral persistence: Infections and 

autoimmune disease, 19(1) Clinical Microbiology Reviews, 80-94 (2006) [Pet. Ex. 16(e)]. 

34 Susan van Alst et al., Bystander activation of irrelevant CD4+T cells following antigen-specific vaccination 

occurs in the presence and absence of adjuvant. 12(5) PLoS One, e0177365 (2017) [Pet. Ex. 17(a)].

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 19 of 25
20

generating pro-inflammatory cytokines which signaled activation and replication of cytotoxic T 

cells or B cells specific to the flu vaccine, but also of heterologous T or B cells which attacked 

the cells in the vascular walls. Tr. 130-33. She testified that heterologous T or B cells would be 

activated to produce anti-IgE receptor antibodies that would bind to the mast cells causing 

episodic degranulation. Tr. 133. This anti-IgE receptor antibody caused the clinical 

manifestation observed in G.C. Pet. Ex. 6 at 8. Additionally, antigen-antibody complexes are 

involved in the vasculitis. Id. The antigen-antibody complexes embed themselves in the vessels, 

fixing complement and produce the vasculitis. Id. 

The respondent and Dr. Schroeder first argued that there are no epidemiological studies 

connecting the flu vaccine to vasculitis. Dr. Schroeder referred to the Bonetto et al. article to 

support the assertion that existing medical literature does not allow establishing a causative link 

between vaccination and vasculitis. In Bonetto et al., the authors conducted a systemic medical 

literature review of 75 studies that included case reports, controlled trials and 

retrospective/observational studies that related to vasculitis following immunization. Resp. Ex. I 

at 2. However, the article also states that “standard diagnostic criteria for vasculitis are limited 

and rarely applied; therefore, it is not possible to draw any conclusion on causality based on the 

current data.” Id. at 8. The article notes that the vaccine most often reported to precede 

vasculitis is the influenza vaccine. Id. at 9. Further, the article states that the authors of 43 case 

reports considered that a link between vasculitis and vaccination was possible or likely, 

hypothesizing that the mechanism may involve immune complex deposition in the blood vessel 

wall. Id. 

Furthermore, an editorial by Zafrir et al.

35observed that the most common autoimmune 

phenomena described following the flu vaccine were different vasculitic diseases. Pet. Ex. 17(c) 

at 2. The authors note that the 33 case reports of post-influenza vaccination vasculitides reported 

are rare compared with the amount of influenza vaccines administered yearly but pose a possible 

link between the vaccination and autoimmunity. Id. Dr. Schroeder argued that the higher case 

reports involving the flu vaccine and vasculitis was due to the high frequency in which the flu 

vaccine is administered. Tr. 280; Resp. Ex. J at6.

Dr. Schroeder conceded that bystander activation is a means by which autoantibodies can 

be produced, leading to an autoimmune disease. Tr. 213-214. He argued that for bystander 

activation to work, the specific autoimmune antibodies would have had to have been present 

before hand. Tr. 253. However, the essence of the bystander activation theory is that nonspecific dormant autoimmune cells can be activated in the lymph nodes by the cytokines 

stimulated in response to the foreign antigen. Dr. Byers testified that there were likely quiescent 

B cells present for some time and it was the massive release of cytokines that activated those 

autoreactive B cells to start spewing out her IgM antibodies which were then seen in the biopsy. 

Tr. 350. Dr. Byers explained that after G.C. received the flu vaccine, the IgM anti-IgE receptor 

antibodies produced the rash and also produced the antigen-antibody complexes, that embedded 

themselves into the vessels, fixing complement, which is what led to the vasculitis. Tr. 351; Pet. 

Ex. 6 at 8. 

 

35 Yaron Zafrir et al., Post-Influenza Vaccination Vasculitides: A Possible New Entity, 15 Journal of Clinical 

Rheumatology, 269-270 (2009) [Pet. Ex. 17(c)].

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 20 of 25
21

Then Dr. Schroeder argued that bystander activation is a less efficient process for 

generating B cells. Tr. 253. He testified that “had the reaction occurred a month after the 

vaccination...there would have been time.” Tr. 254. He opined that five days was too fast for a 

bystander activation to be the mechanism for triggering G.C. urticarial vasculitis. Tr. 256.

However, he did not account for the fact that G.C’s immune system had likely been primed by 

prior flu vaccines, as this was her third flu vaccination. 

After review of the testimony and the medical literature I conclude that bystander 

activation is a reasonable and reputable theory that is recognized in the literature and can explain 

the role of the vaccine in triggering the occurrence of autoimmune vasculitis in this case.

B. Althen Prong Two: Logical Sequence of Cause and Effect

1. Legal Standard

To satisfy Althen prong two, petitioner must show, by a preponderance of the evidence a 

“logical sequence of cause and effect showing that the vaccination was the reason for the injury.” 

Althen at 1278. Even if the vaccination can cause the injury, petitioner must show “that it did so 

in [this] particular case.” Hodges v. Sec’y of Health & Human Servs., 9 F.3d 958, 962 n.4 (Fed. 

Cir. 1993). 

Proof of Althen prong two requires a logical explanation as to how the vaccine did cause 

the injury in the petitioner. “A logical sequence of cause and effect means what it sounds likethe claimant’s theory of cause and effect must be logical.” Capizzano v. Sec’y of Health & 

Human Servs., 440 F.3d at 1326. 

2. Discussion & Conclusion

Dr. Byers offered the theory of bystander activation to explain how the third flu vaccine 

G.C. received can cause urticarial vasculitis. Dr. Byers also opined that this theory fit the present 

case because the clinical manifestations of the allergic acute urticaria G.C. experienced prior to 

the vaccination was markedly different from the symptoms she experienced after receiving the 

vaccination. Pet. Ex. 12 at 2. 

Dr. Byers explained that the rash and hives accompanied by bruising and swelling that 

G.C. experienced after the vaccination was more consistent with a vasculitis. Tr. 349; Pet. Ex. 

12 at 2. Dr. Schroeder, on the other hand, argued that there was “no proof that the skin 

manifestations before and after vaccination were different....there is no documentation in the 

medical records that distinguishes the rashes before and after vaccination from each other.” 

Resp. Ex. A at 12. 

Dr. Schroeder’s assessment that G.C.’s skin manifestations” were the same before and 

after the vaccine was limited to the presentation of the urticaria and failed to consider the 

ongoing vasculitic symptoms G.C. experienced post-vaccination. The vasculitic symptoms of 

joint pain, swelling and bruising first manifested five days after the flu vaccine and continued 

with some regularity. Tr. 338. However, Dr. Schroeder apparently disregarded Ms. Contino’s 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 21 of 25
22

reports of joint pain, swelling and reoccurring bruises to physicians, leading him to an unduly 

restrictive description of G.C.’s post-vaccination condition. During cross-examination, Dr. 

Schroeder acknowledged that the medical records relating to G.C.’s hives from September and 

October do not indicate that G.C. experienced any swelling, bruising or joint pain in association 

with presentation of the hives. Tr. 300-02. He testified, “All I have is a description of a rash, 

and the fact that they were treating her for urticaria. So I presume that she had an urticarial rash, 

if they were treating her for urticaria. She had an urticarial rash before, she had an urticarial rash 

after, right? And so it seems to me that it’s the same condition.” Tr. 313. However, it was 

evident from the course of treatment and diagnostic assessments of G.C. at the Cleveland Clinic 

and Johns Hopkins that the physicians were considering something considerably different than 

Benadryl responsive hives. 

In his first report, Dr. Schroeder offered two alternative explanations as to why G.C.

experienced markedly different symptoms five days after the vaccine compared to the symptoms 

she experienced in the fall. First, Dr. Schroeder associated the different symptoms G.C. 

experienced in December to the change in temperature from Maryland to Florida. He explained 

that the “...the episode on December 8, 2013 occurred during travel from Maryland to Florida in 

December, a period where the temperature differential between these two states is exacerbated.” 

Resp. Ex. A at 8-9. Dr. Schroeder then attributed the different symptomology to a viral 

infection. He stated that “At Florida Hospital, her symptoms were judged by her emergency 

room physicians to be most consistent with a viral exanthema.” Id. at 9. He continued by 

stating, “...these particular symptoms with fever resolved and did not recur. Instead, the patient 

returned to the pattern of a rash alone occurring every two to three weeks that held sway since 

September of 2013.” Id (emphasis added). When Dr. Schroeder was asked by the Court if given 

the knowledge of the full history of the development of this condition, which the emergency 

room doctor did not have, whether he still attributed the different symptomology that appeared in 

G.C. in Florida to a viral exanthem, he responded, “I can’t say to be frank.” Tr. 309.

As described in more detail above, the rashes and hives G.C. experienced in the fall of 

2013 were short-lived and resolved quickly when given Benadryl. See Pet. Ex. 1(a) at 98; Tr. 9-

10. A physical examination of G.C. on September 13, 2013 found her “well appearing/acting, 

not itching, rash is nontender.” Pet. Ex. 1 at 98. It was recommended that the rash be treated 

with Benadryl and an oatmeal bath. Id. When assessed the next month by Dr. Korff, she 

diagnosed G.C. with dermatographic urticaria and recommended treating the symptoms with 

Benadryl versus daily use of a long acting antihistamine. Pet. Ex. 1(a) at 70. Ms. Contino 

testified that the hives in the fall were not accompanied by fever, extreme pain or bruising. Tr. 8; 

10-13.

Five days after G.C. received the flu vaccination on December 3, 2013, G.C. began to 

exhibit hives and rashes across her abdomen and thighs. Pet. Ex. 2 at 7; Tr. 14-5. Six days after 

receiving the vaccine, G.C,’s hives and rash spread across her body, accompanied by pain, a 

fever of 101 degrees and bruises accompanying the rash. Pet. Ex. 4 at 16-17; 23-24; Tr. 14-24. 

At the emergency room in the Florida Hospital, G.C. was treated with steroids that reduced the 

swelling in G.C.’s legs, but the bruises remained. Tr. 20-21. Ms. Contino explained that G.C.’s 

symptoms of swelling and joint pain, along with the rashes and bruises reappeared about a month 

after the flu vaccine and continued a few times a week. Tr. 338-43. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 22 of 25
23

During the hearing, Dr. Byers explained that in the fall of 2013, the medical professionals

that treated G.C. for hives did not suspect any systemic involvement. Tr. 136. Instead, G.C. was 

treated with Benadryl and the urticaria resolved within a few hours. Id. However, when G.C. 

saw Dr. Silber on February 3, 2014 for recurrent rash and joint pain, he suspected a systemic 

disease, diagnosed G.C. with “probable vasculitis” and recommended G.C. see a pediatric 

rheumatologist. Pet. Ex. 1 at 60. 

At the Cleveland Clinic, based on the reported symptoms by Mrs. Contino and the 

photographs Ms. Contino presented to Dr. Zeft, G.C. was diagnosed with “hemorrhagic edema of 

infancy (a form of vasculitis) triggered by influenza vaccination. Preceding urticaria may be 

idiopathic or potentially part of an illness spectrum.” Id. at 58. Dr. Byers explained that Dr. 

Zeft’s diagnosis of “hemorrhagic edema of infancy” was the second time in the medical records 

that a medical professional was considering vasculitis as an explanation for G.C.’s symptoms. 

Tr. 93-94. She explained that “hemorrhagic edema of infancy,” is small vessel vasculitis. Id. 

Dr. Zeft recommended a complete blood count with differential, a urinalysis, complement 

metabolic panel to test for C3 or C4 and a serum immunoglobulin test, specifically looking for 

elevated IgA. Pet. Ex. 1 at 58; Tr. 94. At Johns Hopkins, Dr. Sule became concerned with 

G.C.’s elevated protein/creatine ratio and recommended G.C. undergo a skin biopsy and repeat 

urinalysis. Pet. Ex. 2 at 3. The skin biopsy performed on March 27, 2014 confirmed the 

ultimate diagnosis of urticarial vasculitis. Id. at 10. 

From then on, G.C. has been treated with steroids and immunosuppressive drugs. Tr. 41; 

see also Pet. Ex. 2 at 10-18. G.C. continues to experience leg and joint pain, along with rash 

flare-ups and mouth ulcers. Pet. Ex. 15 at 4; Tr. 49-50, 343. 

While the “history of present illness,” in the medical records from the Cleveland Clinic 

and the first two appointments from Johns Hopkins somewhat confused the occurrences of the 

acute urticaria G.C. experienced in the fall of 2013, all three records are consistent in noting that 

after G.C. received a flu vaccination, she experienced bruising, swelling and joint pain that 

continued after seeking treatment at the emergency room of Florida Hospital. See Pet. Ex. 2 at 4, 

7; Pet. Ex. 9 at 3. Taken as a whole, the evidence indicates that G.C. did not simply experience a 

“rash alone,” after she returned from Florida, as asserted by Dr. Schroeder, but instead G.C’s

rashes post-vaccination were accompanied with joint pain, bruising and swelling, all of which 

were absent in the fall of 2013. Additionally, post-vaccination, G.C. consistently had abnormal 

pr/cr ratio which was concerning to physicians to Johns Hopkins and was indicative of systemic 

involvement. See Pet. Ex. 2(a) at 12. 

Following the theory proposed by Dr. Byers, an extensive review of the medical records 

and after hearing the compelling testimony of Mrs. Contino, I conclude that the petitioner has set 

forth a logical cause and effect relationship between the flu vaccination and G.C.’s urticarial 

vasculitis. G.C.’s symptoms post-vaccine are consistent with the medical literature describing 

symptoms of autoimmune vasculitis, and more importantly, those symptoms are distinct from the 

symptoms that G.C. experienced in the fall of 2013. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 23 of 25
24

C. Althen Prong Three

1. Legal Standard

Althen prong three requires establishing a “proximate temporal relationship” between the 

vaccination and the injury alleged. Althen at 1281. That term has been equated to the phrase 

“medically-acceptable temporal relationship.” Id. A petitioner must offer “preponderant proof 

that the onset of symptoms occurred within a timeframe which, given the medical understanding 

of the disorder’s etiology, it is medically acceptable to infer causation.” de Bazan v. Sec’y of 

Health & Human Servs., 539 F.3d 1347, 1352 (Fed. Cir. 2008). The explanation for what is 

medically acceptable timeframe must also coincide with the theory of how the relevant vaccine 

can cause an injury (Althen prong one). Id. at 1352. 

2. Discussion and Conclusion

Petitioner argued that there was an acceptable temporal relationship between G.C.’s flu 

vaccination on December 3, 2014 and the onset of the first symptoms of urticarial vasculitis five 

days later, on December 8, 2014. 

With respect to the temporal relationship between the vaccine and onset of G.C.’s 

symptoms, Dr. Byers opined that the onset of three to twenty- one days is an appropriate medical 

onset of symptoms based upon the relevant medical literature. Pet. Ex. 6 at 8; Tr. 109-112. 

As such, Dr. Byers contended that the temporal association of three to five days is also 

supported by medical literature. She cited to an article by Felicetti et al.36 to support the 

proposition that vasculitides have been reported as an adverse event following vaccination, with 

more frequent reports in association with influenza vaccines than with any other vaccine in three 

international vaccine reporting databases, including VAERS. Pet. Ex. 16(d) at 3. This article 

also notes that across the three databases, vasculitides appear to be more frequently reported in 

the pediatric population, among females and with a time to onset within 10 days from the 

vaccination. Id. at 6. Dr. Byers also referred to a case report by Cao and Sun37 where an elderly 

gentleman presented to an emergency room five days after receiving the flu vaccine with 

extensive rash, fever and joint pain in his hips, knees and ankles. Pet. Ex. 16(b) at 2. He was 

diagnosed with leucocytoclastic vasculitis. Id. Another case report by Liu et al.38 indicated the 

onset of painful erythematous eruptions on the patient’s trunk, arms and thighs three days after 

receiving an H1N1 flu vaccination. Pet. Ex. 16(o). 

Further, Dr. Byers asserted that five days is particularly medically appropriate because 

this was the third flu vaccine G.C. had received. Tr. 87. The Agmon-Levin article states that a 

 

36 Patrizia Felicetti et al., Spontaneous reports of vasculitis as an adverse event following immunization: A 

descriptive analysis across three international databases, 34 Vaccine 6634-6640 (2016) [Pet. Ex. 16(d)].

37 Sissi Cao and Dongemi Dongemi, Leucocytoclastic vasculitis following influenza vaccination, BMJ Case Rept. 

(2017), doi: 10.1136/bcr-2016-217755 [Pet. Ex. 16(b)]. 

38 Po-Yu Liu et al., Cutaneous Vasculitis Following Influenza Vaccination, 49 Inter. Med. 2187-2188 (2010) [Pet. 

Ex. 16(o)]. 

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 24 of 25
25

second exposure to the same antigen might elicit a response within a shorter period. Pet. Ex. 

8(b) at 2. 

Additionally, this court has previously awarded entitlement where the petitioner’s onset 

of symptoms of urticarial vasculitis began only a few days after the flu vaccination. McElroy v. 

Sec’y of Health & Human Servs., No. 11-679, 2012 WL 1739873 at *4 (Fed. Cl. Spec. Mstr. 

Apr. 13, 2012). In that case, the petitioner received the flu vaccine on October 25, 2008 and on 

November 6, 2008, complained of a travelling urticaric rash on her trunk and extremities for two 

weeks, putting onset almost immediately after the vaccination. Id (emphasis added). 

Respondent’s expert, Dr. Schroeder, opined that the hives G.C. experienced in the fall of 

2013 was the beginning stages of chronic urticaria. Resp. Ex. A at 10; Tr. 224. He testified that 

in the fall of 2013, G.C’s hives could not be classified as “chronic urticaria” because the hives 

had not yet presented for six weeks. Tr. 225. He also asserted that the urticarial symptoms that 

predated the vaccination were no different in presentation than the symptoms G.C. experienced 

after the vaccination, aside for the “severe episode of skin manifestations,” that occurred in 

Florida. Resp. Ex. A at 8. However, as discussed in greater detail above, the hives G.C. 

experienced in the fall appeared to be different in both symptomology and mechanism of 

activation. The post-vaccination skin manifestations were accompanied by bruises, swelling, 

joint pain and kidney issues that were not present during the late summer and early fall episodes.

The August/September episodes appeared to be an allergic reaction, responsive to Benadryl and 

the post-vaccination condition being autoimmune, requiring immunomodification drugs and 

ongoing steroid treatment. 

The post-vaccination condition appears to be autoimmune as opposed to allergic and five 

days is frequently period for onset for autoimmune conditions. There appears to be a 

preponderance of the evidence that G.C. experienced the initial presentation of her urticarial 

vasculitis within a medically appropriate timeframe following the flu vaccine on December 3, 

2013. 

VI. CONCLUSION

After a review of the entire record, I conclude that petitioner has established a reliable 

theory that the flu vaccination G.C. received on December 3, 2013 was the cause-in-fact of her 

urticarial vasculitis. Accordingly, petitioner is entitled to compensation. A separate damages 

order will be issued. 

IT IS SO ORDERED. 

s/Thomas L. Gowen

Thomas L. Gowen

Special Master

Case 1:15-vv-00773-UNJ Document 66 Filed 09/05/19 Page 25 of 25